Phase 2 N=40 An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects
Fibrodysplasia Ossificans Progressiva
Primary: Percentage of Responders at Week 6 — 100; 88.9; 88.9 percentage of subjects — p=0.1664
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
Prostate Cancer
Primary: Change in Patient Management — 6; 15; 21; 21 Participants
Phase 2 N=180 Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Cervical High Grade Squamous Intraepithelial Lesion
Primary: Cervical HSIL — 46; 39 Participants — p=.29
Phase 2 N=5 Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study
Hypertension · Vitamin D Deficiency
Primary: Change in Mean Blood Pressure From Baseline to 12 Weeks — 4.3 mmHg
Phase 2 N=22 Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia · Stage 0 Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I)…
Phase 2 N=31 A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia · Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicity (DLT) (Phase lb) — 1; 3; 2 Participants
Phase 2 N=8 Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Castleman Disease · Multicentric Castleman Disease · Giant Lymph Node Hyperplasia
Primary: Percentage of Participants With an Overall Clinical Benefit Response — 63; 100; 50; 67 percentage of participants
Phase 2 N=170 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
Adenosquamous Lung Carcinoma · Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma
Primary: Percentage of Participants Alive Without Progression (Progression-free Survival) — 60.4; 51.3 percentage of participants — p=0.7563
Phase 2 N=14 Effects of Marijuana on Symptoms of OCD
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive-Compulsive Challenge Scale (YBOC-CS) — 17.45; 17.00; 17.09; 13.36 score on a scale — p=.577
Phase 2 N=41 A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Primary: Change From Baseline in ATPmax (Maximal ATP Synthetic Rate) — 0.17; 0.12; 0.09; 0.06 mM/sec
Phase 2 N=37 Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Stage I Mantle Cell Lymphoma · Stage II Contiguous Mantle Cell Lymphoma · Stage II Non-Contiguous Mantle Cell Lymphoma
Primary: Proportion of Patients Experiencing a Complete Response — .62 Proportion of participants
Phase 2 N=20 A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
Duchenne Muscular Dystrophy (DMD)
Primary: Change From Baseline to Part 2 in the Value of Muscle Fiber Area (MFA) % Comparing the Histology Biopsies Before and After 12 Months of Treatment With Givinostat…
Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
Phase 2 N=21 A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
Visual Acuity · Geographic Atrophy · Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 1- Treated Eye — 0.132 logMAR
Phase 2 N=3 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Recurrent Esophageal Carcinoma
Primary: Progression-free Survival (PFS) — 0 Participants